Time Posted:2024-04-18 15:30
On the evening of April 17, Healthy Yuan announced that the Phase III multicenter clinical trial of its innovative drug product TG-1000 capsules had met its primary endpoint. The company will soon communicate with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) regarding the marketing application for this drug to treat influenza, and will promote the drug's listing process.
Time Posted:2024-03-26 12:00
On March 20, a "Public Welfare Chronic Disease Prevention and Treatment Project" jointly launched by Healthy Yuan, Lizhu Group, and the Tibet Qizheng Charity Foundation arrived in Bomê County, Linzhi City, Tibet Autonomous Region. A drug donation ceremony was held in front of the county committee building in Zammu. Zhoma Yangjin, the deputy county magistrate; Niu Haiyan, director of the county health and health commission; relevant personnel from the county people's hospital and various township health centers; volunteers from the Tibet Qizheng Charity Foundation; and volunteers from Healthy Yuan and Lizhu Group attended the event.
Time Posted:2024-03-21 18:00
On March 20, 2024, HealthGen Biotech Group and Bayer signed an exclusive license agreement for the development, commercialization, and production of a small molecule inhibitor in China. This is also the first time HealthGen has introduced an innovative drug pipeline in the respiratory field from a leading global multinational company.
Time Posted:2024-03-08 14:15
In recent years, with the continuous increase in the number of pediatric patients in China, the market demand for pediatric drugs has been growing. However, there is a shortage of pediatric-specific drugs, and the lack of appropriate dosage forms and specifications, as well as the missing information on pediatric drug use in drug instructions, are still quite common.
Time Posted:2024-01-27 09:30
On January 26, 2024, Healthy Yuan Pharmaceutical Group made another breakthrough in its innovative drug R&D layout. It reached a cooperation agreement with Tongbo'an Bio for the exclusive rights in mainland China to BA2101, a long-acting anti-IL-4Rα monoclonal antibody injection for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Time Posted:2024-01-26 18:15
On January 24, 2024, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), an innovative research-oriented comprehensive pharmaceutical group, and Jiangsu Qunxin Biopharmaceutical Co., Ltd. (hereinafter referred to as "Qunxin Bio"), focusing on biological therapies for autoimmune and allergic diseases, jointly announced that the two parties have reached a strategic cooperation on the monoclonal antibody QX008N and signed an exclusive license agreement for the China region (including Hong Kong and Macao).
Time Posted:2024-01-23 16:48
Recently, HealthGen (600380.SH) disclosed its "Investor Relations Activity Record Table for December 2023 and January 2024", which shows that 31 institutions have conducted on-site investigations of HealthGen since December last year. Public information indicates that many mainstream institutions have long been paying attention to the company's dynamics and are optimistic about its future development and investment value.